http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5680441-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate | 2006-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe72fed7e898a31f5f85bec169da257b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd669c0ce79c8bbda5aeb3da04096c71 |
| publicationDate | 2006-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-5680441-A2 |
| titleOfInvention | COMBINATIONS OF A CATEPSIN K INHIBITOR AND A BISFOFONATE IN THE TREATMENT OF OSEA METASTASIS, TUMOR GROWTH AND OSEA LOSS INDUCED BY TUMOR |
| abstract | 1. A pharmaceutical preparation comprising in combination a bisphosphonate of formula I, or a physiologically acceptable and divisible ester or a salt thereof wherein X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C1-C4 alkyl , or alkanoyl R is hydrogen or C1-C4 alkyl and Rx is a side chain containing an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof; and) a cat K inhibitor of the formula V, or a physiologically acceptable and divisible ester or a salt thereof wherein R1 is optionally substituted (aryl, aryl-lower alkyl, lower alkenyl, lower alkynyl, heterocyclyl or heterocyclyl-lower alkyl) ; R2 and R3 together represent lower alkylene, optionally interrupted by O, S, or NR6, to form a ring with the carbon atom to which they are attached, and R6 is hydrogen, lower alkyl or lower arylalkyl; R4 and R5 are independently H , or optionally substituted (lower alkyl or aryl-lower alkyl), -C (O) OR7, or -C (O) NR7R8, wherein R7 is optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl, bicycloalkyl or heterocyclyl), and R8 is H, or optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl, bicycloalkyl or heterocyclyl); or R4 and R5 together represent lower alkylene, optionally interrupted by O, S or NR6, ... |
| priorityDate | 2003-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.